Tesamorelin Side Effects: Safety Signals and Warnings
Tesamorelin safety concerns are compound-specific. The main listed side effects are Injection site reactions (erythema, pruritus), Arthralgia, and Peripheral edema. The main warning signals are Contraindicated in patients with active malignancy, Disruption of the hypothalamic-pituitary axis from hypophysectomy, hypopituitarism, or pituitary tumor surgery, and Known hypersensitivity to tesamorelin or mannitol.
Direct Answer
Tesamorelin is FDA-approved for HIV-related lipodystrophy and has the strongest human evidence of any GHRH analog in this library - multiple Phase 3 RCTs demonstrating significant visceral fat reduction. Outside its approved indication, human data is limited. For research into GHRH-pathway GH stimulation, tesamorelin provides the reference standard with actual regulatory approval behind it.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Growth Hormone
- Best for
- HIV-associated lipodystrophy, visceral fat reduction, GHRH-mediated GH research
Reported Side Effects
- Injection site reactions (erythema, pruritus)
- Arthralgia
- Peripheral edema
- Myalgia
- Paresthesia
- Elevated IGF-1 levels
Warnings
- Contraindicated in patients with active malignancy
- Disruption of the hypothalamic-pituitary axis from hypophysectomy, hypopituitarism, or pituitary tumor surgery
- Known hypersensitivity to tesamorelin or mannitol
- Should not be used during pregnancy
- May cause fluid retention and glucose intolerance
Known or Plausible Interactions
- Cortisone and other corticosteroids (may reduce GH response)
- Insulin and oral hypoglycemics (GH can impair glucose tolerance)
- Drugs metabolized by CYP450 (GH/IGF-1 may alter metabolism)
Regulatory Context
FDA approved (Egrifta). Prescription required. Schedule: Not a controlled substance.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Visceral Adipose Tissue Reduction (Level A), IGF-1 Increase (Level A), and Cognitive Function (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-06-02 |
Related Guides
How to Cite This Page
ExaminePeptides. "Tesamorelin Side Effects: Safety Signals and Warnings." Last reviewed 2026-06-02. https://examinepeptides.com/answers/tesamorelin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.